

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 48/00, C12N 15/00, C12Q 1/00, C07K 7/00		A1	(11) International Publication Number: WO 95/21630 (43) International Publication Date: 17 August 1995 (17.08.95)
(21) International Application Number: PCT/US95/01446 (22) International Filing Date: 26 January 1995 (26.01.95) (30) Priority Data: 08/195,186 14 February 1994 (14.02.94) US 08/196,630 15 February 1994 (15.02.94) US 08/292,492 18 August 1994 (18.08.94) US (71) Applicant: LUDWIG INSTITUTE FOR CANCER RE- SEARCH [US/US]; 1345 Avenue of the Americas, New York, NY 10105 (US). (72) Inventors: VAN DER BRUGGEN, Pierre; Avenue Hippocrate 74, UCL 7459, B-1200 Brussels (BE). SZIKORA, Jean- Pierre; Avenue Hippocrate 74, UCL 7459, B-1200 Brussels (BE). COULIE, Pierre; Avenue Hippocrate 74, UCL 7459, B-1200 Brussels (BE). WILDMANN, Claude; Avenue Hippocrate 74, UCL 7459, B-1200 Brussels (BE). BOEL, Pascale; Avenue Hippocrate 74, UCL 7459, B-1200 Brussels (BE). BOON-FALLEUR, Thierry; Avenue Hippocrate 74, UCL 7459, B-1200 Brussels (BE). (74) Agent: HANSON, Norman, D.; Felfe & Lynch, 805 Third Avenue, New York, NY 10022 (US).			(81) Designated States: AU, CA, CN, FI, JP, NO, NZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: METHOD FOR IDENTIFYING INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY			
(57) Abstract The invention relates to the identification of complexes of HLA-C-clone 10 and MAGE-1 derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

METHOD FOR IDENTIFYING INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY

RELATED APPLICATIONS

This application is a continuation-in-part of copending application Serial No. 08/195,186 filed February 14, 1994, which is a continuation-in-part of U.S. Application Serial No. 08/008,446, filed January 22, 1993. It is also a continuation-in-part of Serial No. 08/196,630 filed February 15, 1994.

FIELD OF THE INVENTION

This invention relates to various therapeutic methodologies derived from the recognition that certain abnormal cells present complexes of HLA-Cw*1601 (previously referred to as HLA-C-clone 10) (Bodmer et al., Tissue Antigens 44: 1 (1994)) and peptides derived from a molecule referred to as MAGE-1 on their surfaces. In addition, it relates to the ability to identify those individuals diagnosed with conditions characterized by cellular abnormalities whose abnormal cells present this complex.

BACKGROUND AND PRIOR ART

The process by which the mammalian immune system recognizes and reacts to foreign or alien materials is a complex one. An important facet of the system is the T cell response. This response requires that T cells recognize and interact with complexes of cell surface molecules, referred to as human leukocyte antigens ("HLA"), or major histocompatibility complexes ("MHCs"), and peptides. The peptides are derived from larger molecules which are processed by the cells which also present the HLA/MHC molecule. See in this regard Male et al., Advanced Immunology (J.P. Lipincott Company, 1987), especially chapters 6-10. The interaction of T cell and complexes of HLA/peptide is restricted, requiring a T cell specific for a particular combination of an HLA molecule and a peptide. If a specific T cell is not present, there is no T cell response even if its partner complex is

5 present. Similarly, there is no response if the specific
complex is absent, but the T cell is present. This mechanism
is involved in the immune system's response to foreign
materials, in autoimmune pathologies, and in responses to
10 the mechanisms by which proteins are processed into the HLA
binding peptides. See, in this regard, Barinaga, Science 257:
880 (1992); Fremont et al., Science 257: 919 (1992); Matsumura
et al., Science 257: 927 (1992); Latron et al., Science 257:
964 (1992).

15 The mechanism by which T cells recognize cellular
abnormalities has also been implicated in cancer. For
example, in PCT application PCT/US92/04354, filed May 22,
1992, published on November 26, 1992, as WO92/20356 and
incorporated by reference, a family of genes is disclosed
20 which are processed into peptides which, in turn, are
expressed on cell surfaces, and can lead to lysis of the tumor
cells by specific CTLs. These genes are referred to as the
"MAGE" family, and are said to code for "tumor rejection
antigen precursors" or "TRAP" molecules, and the peptides
25 derived therefrom are referred to as "tumor rejection
antigens" or "TRAS". See Traversari et al., Immunogenetics
35: 145 (1992); van der Bruggen et al., Science 254: 1643
(1991), for further information on this family of genes.

30 In U.S. patent application Serial Number 938,334, the
disclosure of which is incorporated by reference, nonapeptides
are taught which bind to the HLA-A1 molecule. The reference
teaches that given the known specificity of particular
peptides for particular HLA molecules, one should expect a
particular peptide to bind one HLA molecule, but not others.
35 This is important, because different individuals possess
different HLA phenotypes. As a result, while identification
of a particular peptide as being a partner for a specific HLA
molecule has diagnostic and therapeutic ramifications, these
are only relevant for individuals with that particular HLA
40 phenotype. There is a need for further work in the area,
because cellular abnormalities are not restricted to one

5 particular HLA phenotype, and targeted therapy requires some knowledge of the phenotype of the abnormal cells at issue.

In a patent application filed on December 22, 1992 in the name of Boon-Falleur et al., entitled "Method For Identifying Individuals Suffering From a Cellular Abnormality, Some of
10 Whose Abnormal Cells Present Complexes of HLA-A2/Tyrosinase Derived Peptides and Methods for Treating said Individuals", the complex of the title was identified as being implicated in certain cellular abnormalities. The application does not suggest, however, that any other HLA molecules might be
15 involved in cellular abnormalities.

The prior presentation of MAGE-1 by an HLA-A molecule, as disclosed supra, also does not suggest that the protein can be presented by another HLA molecule. Thus, it is surprising that the very MAGE molecule presented by HLA-A1 has now been
20 shown to be presented by HLA-Cw*1601. While the prior research is of value in understanding the phenomenon, it in no way prepares the skilled artisan for the disclosure which follows.

BRIEF DESCRIPTION OF THE FIGURE

25 Figure 1 depicts experiments involving transfection of COS-7 with coding sequences for MAGE-1 and HLA-Cw*1601.

Figure 2A sets forth results of a ⁵¹Cr release assay using MZ2 cells infected with Epstein Barr Virus, which had been incubated with the peptide of SEQ ID NO: 4, for 30 minutes.
30 The effector cells were from CTL 81/12.

Figure 2B parallels figure 2A, the only difference being that the effector was CTL 82/35.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Example 1

35 In the experiments which follow, various melanoma cell lines were used. These were obtained from melanoma patients identified as MZ2 and LB73. Cell lines MZ2-MEL.43, MZ2-MEL-3.0, and MZ2-MEL 3.1 are cloned sublines of MZ2-MEL, and are described in Van den Eynde et al., Int. J. Canc. 44: 634
40 (1989), as well as PCT patent application WO92/20356 (Nov. 26, 1992), both disclosures being incorporated by reference and in

5 their entirety herewith. Cell line LB73-MEL was derived from patient LB73 in the same manner as the other cell lines described herein.

10 Samples containing mononuclear blood cells were taken from patient MZ2. A sample of the melanoma cell line MZ2-MEL.43 was irradiated, and then contacted to the mononuclear blood cell containing samples. The mixtures were observed for lysis of the melanoma cell lines, this lysis indicating that cytolytic T cells ("CTLs") specific for a complex of peptide and HLA molecule presented by the melanoma cells were present
15 in the sample.

The lysis assay employed was a chromium release assay following Herin et al., Int. J. Cancer 39:390-396 (1987), the disclosure of which is incorporated by reference. The assay, however, is described herein. The target melanoma cells were
20 grown in vitro, and then resuspended at 10^7 cells/ml in DMEM, supplemented with 10 mM HEPES and 30% FCS, and incubated for 45 minutes at 37°C with 200 μ Ci/ml of Na(^{51}Cr)O₄. Labelled cells were washed three times with DMEM, supplemented with 10 mM Hepes. These were then resuspended in DMEM supplemented
25 with 10 mM Hepes and 10% FCS, after which 100 μ l aliquots containing 10^3 cells, were distributed into 96 well microplates. Samples of PBLs were added in 100 μ l of the same medium, and assays were carried out in duplicate. Plates were centrifuged for 4 minutes at 100g, and incubated for four
30 hours at 37°C in a 5.5% of CO₂ atmosphere.

Plates were centrifuged again, and 100 μ l aliquots of supernatant were collected and counted. Percentage of ^{51}Cr release was calculated as follows:

$$\begin{aligned} 35 \quad \% \text{ } ^{51}\text{Cr} \text{ release} &= \frac{(\text{ER}-\text{SR})}{(\text{MR}-\text{SR})} \times 100 \end{aligned}$$

where ER is observed, experimental ^{51}Cr release, SR is spontaneous release measured by incubating 10^3 labeled cells
40 in 200 μ l of medium alone, and MR is maximum release, obtained by adding 100 μ l 0.3% Triton X-100 to target cells.

5 Those mononuclear blood samples which showed high CTL activity were expanded and cloned via limiting dilution, and were screened again, using the same methodology.

These experiments led to the isolation of several CTL clones from patient MZ2 including CTL clone "81/12".

10 The experiment was repeated as described, using both cell line MZ2-MEL 3.0 and MZ2-MEL 3.1. The results indicated that clone 81/12 recognized both MZ2-MEL.43 and MZ2-MEL 3.0, but not MZ2-MEL 3.1. The antigen being recognized by 81/12 is referred to hereafter as "antigen Bb".

15 Example 2

In view of prior work, as summarized supra, it was of interest to determine the HLA class 1 profile for patient MZ2. This was determined following standard methodologies, which are now set forth. To obtain cDNA clones coding for the genes of the HLA class 1 molecules of the patients, a cDNA library was prepared, starting with total mRNA extracted from cell line MZ2-MEL.43, using well known techniques not repeated here. The library was inserted into plasmid pcD-SR α , and then screened, using an oligonucleotide probe containing a sequence common to all HLA class 1 genes, i.e.:

5'-ACTCCATGAGGTATTTC-3'

(SEQ ID NO: 1)

30 One clone so identified was clone IC4A7 which, upon sequencing, was found to be functionally equivalent, if not identical to, HLA-Cw*1601, a well known human leukocyte antigen molecule. The sequence of the DNA coding for HLA-Cw*1601 is given at, e.g. Cianetti et al., Immunogenetics 29: 80-91 (1989), where it was named HLA-C clone 10 and the sequence is available under GENBANK accession number HUMMHCACA. An updated sequence is reported by Zemmour et al., Immunogenetics 37: 239-250 (1993), the disclosure of which is incorporated by reference in its entirety, as is 40 Cianetti et al., supra. The Zemmour sequence is also available in the EMBL sequence bank.

5 Example 3

It was of interest to determine if the HLA molecule identified supra presented a mage derived tumor rejection antigen, and if the resulting complex of antigen and HLA molecule was recognized by a CTL clone of patient MZ2. To
10 determine this, recipient cells were transfected with cDNA coding HLA-Cw*1601, and with one of MAGE-1, MAGE-2, or MAGE-3 cDNA. The MAGE-1 cDNA was inserted into plasmid pcDNA I/Amp, while MAGE-2 and MAGE-3 cDNA were inserted into plasmid pcD-SR α .

15 Samples of recipient COS-7 cells were seeded, at 15,000 cells/well into tissue culture flat bottom microwells, in Dulbecco's modified Eagles Medium ("DMEM") supplemented with 10% fetal calf serum. The cells were incubated overnight at 37°C, medium was removed and then replaced by 30 μ l/well of
20 DMEM medium containing 10% Nu serum, 400 μ g/ml DEAE-dextran, 100 μ M chloroquine, and 100 ng of the subject plasmids (i.e., 100 ng of the IC4A7 clone, and 100 ng of the MAGE-cDNA plasmid). Following four hours of incubation at 37°C, the medium was removed, and replaced by 50 μ l of PBS containing
25 10% DMSO. This medium was removed after two minutes and replaced by 200 μ l of DMEM supplemented with 10% FCS.

Following this change in medium, COS cells were incubated for 48 hours at 37°C. Medium was then discarded, and 2000 cells of CTL clone 81/12 were added, in 100 μ l of Iscove
30 medium containing 10% pooled human serum. Supernatant was removed after 24 hours, and TNF content was determined in an assay on WEHI cells, as described by Traversari et al., Immunogenetics 35: 145-152 (1992), the disclosure of which is incorporated by reference.

35 The results, set forth in Figure 1 demonstrate that a tumor rejection antigen, derived from MAGE-1 is presented by HLA-Cw*1601, and is recognized by CTL clone 81/12, whereas expression of MAGE-2 and MAGE-3 does not lead to presentation of the appropriate antigen.

40 Example 4

Following the experiments discussed supra, additional

5 work was carried out to determine the peptide which HLA-Cw*1601 presented.

MAGE-1 cDNA in expression vector pcDNA I/Amp was digested with restriction endonucleases NotI and SphI following the supplier's instructions, and then with exonuclease III. This treatment generated a series of progressive deletions of the MAGE-1 cDNA, starting at the 3' end.

The deletion products were ligated back into pcDNAI/Amp, and then electroporated into *E. coli* strain DH5 α F'IQ, using well known techniques. The transformants were selected with ampicillin (50 ug/ml), and six hundred clones were obtained.

The plasmid DNA was removed from each clone, and was then transfected into COS-7 cells, together with a vector which coded for HLA-Cw*1601. The protocol used follows the protocols described above.

The transfectants were then tested in the TNF release assay described in example 3. This permitted separation of positive and negative clones. The comparison showed that one of the positive clones contained nucleotides 1-730 from the MAGE-1 gene, while a negative clone contained nucleotides 1-706. The sequence of positive and negative clones was compared, and a region of 16 amino acids was identified as putatively containing the antigenic peptide. This sequence is:

Glu His Ser Ala Tyr Gly Glu Pro Arg Lys

Leu Leu Thr Gln Asp Leu

(SEQ ID NO: 2)

Based upon this sequence, a first set of experiments was carried out where synthetic peptides were made, and tested for their ability to render COS-7 cells transfected with HLA-Cw*1601 capable of stimulating lysis. A positive 12 mer was identified, i.e.:

Glu His Ser Ala Tyr Gly Glu Pro Arg Lys Leu Leu

(SEQ ID NO: 3)

Truncation of this 12 mer led to the identification of

5 nonapeptide

Ser Ala Tyr Gly Glu Pro Arg Lys Leu
(SEQ ID NO: 4)

10 as the best stimulator of lysis. Half maximal lysis was
observed at a peptide concentrations of 10 nM.

In experiments not presented herein, but set forth in
Serial No. 08/196,630, filed February 15, 1994 and
incorporated by reference herein, the peptide

15 Ala Ala Arg Ala Val Phe Leu Ala Leu
(SEQ ID NO: 5)

was also found to be presented by HLA-Cw*1601, and lysed by
various cytolytic T cell clones, such as CTL 82/82.

20 Example 5

The identification of two separate peptides being
presented by HLA-Cw*1601 suggested the desirability of an
assay to determine expression of HLA-Cw*1601 in patients.
Serological testing is not a viable option because antibodies
25 to HLA-Cw*1601 are not available. Polymerase chain reaction
("PCR"), however, provided an alternative. Development of a
viable, useful PCR assay for expression of HLA-Cw*1601 based
upon a nested primer system follows.

30 The model described generally by Browning et al., Proc.
Natl. Acad. Sci. USA 90: 2842 (1993), was used. This
reference discusses the use of oligonucleotide primers, the 3'
ends of which are specific for the coding sequence for the HLA
molecule. Using this approach, primers:

35 5'-CAAGCGCCAGGCACAGA-3'
(SEQ ID NO: 6)

and

40 5'-GCCTCATGGTCAGAGACGA-3'
(SEQ ID NO: 7)

5 were synthesized. To test the method, various cell samples from patients were used. Total RNA was extracted, using the well known guanidine isothiocyanate method of Davis et al., Basic Methods in Molecular Biology (Elsevier, New York, 1986), pp. 130. For cDNA synthesis, 2 ug of RNA was diluted with
10 water, and 4 ul of 5x reverse transcriptase buffer. Added were 1 ul each of 10 mM dNTP, 2 ul of a 20 uM solution of oligo (dT), 20 U of RNasin, 2 ul of 0.1M dithiothreitol, and 200 U of MoMLV reverse transcriptase, in a 20 ul reaction volume. The mixture was incubated for 60 minutes at 42°C. To
15 amplify the cDNA, 1% of the cDNA reaction was supplemented with 5 ul of 10x thermostable DNA polymerase buffer, 1 ul each of 10 mM dNTP, 0.5 ul each of 80 uM solution of primers (SEQ ID NO: 6 and 7), 1U of DynaZyme, and water to a final volume of 50 ul. The PCR was carried out for 30 cycles (one minute
20 at 95°C, one minute at 62°C, two minutes at 72°C). The products were diluted to 1/500. Then, a second PCR was carried out, using 1 ul of diluted PCR product, supplemented with 5 ul of 10x thermostable DNA polymerase buffer, 1 ul each of 10 mM dNTP, 0.5 uM each of a 80 uM solution of primers:

25 5'-GAGTGAGCCTGCGGAAC-3'

(SEQ ID NO: 8)

and

5'-CCTCCAGGTAGGCTCTCT-3'

(SEQ ID NO: 9),

30 and 1U of DynaZyme. SEQ ID NO: 8 and SEQ ID NO: 9 represent nucleotide sequences located internally to the first set of primers, i.e., SEQ ID NOS: 6 and 7. Water was added to 50 ul, and 20 cycles of PCR were carried out (one minute 95°C; one
35 minute at 65°C; two minutes at 72°C). The PCR products were then size fractionated on a 1.5% agarose gel in TAE buffer.

This methodology was utilized in two separate sets of experiments. In the first of these, transfectants, prepared as described supra and lysed by cytolytic T cell clones
40 against either SEQ ID NO: 4 or SEQ ID NO: 5 complexed to an HLA molecule were tested. All positive transfectants were

5 found to present the HLA-Cw*1601 molecule on their surfaces. Any sample which generated no PCR products was considered negative. In further experiments using the negative samples, the PCR protocol utilized above was employed a second time but the primers were based upon sequences common to all HLA-C
10 sequences. See Zemmour et al., J. Exp. Med. 176: 937 (1992), incorporated by reference herein. The negative samples proved to be cells expressing different, i.e., non HLA-Cw*1601 HLA-C subtypes.

Example 6

15 In the second set of experiments, the ability of cells, either PBL or tumor, to present peptides via HLA-Cw*1601, was tested. To do this, cells taken from patients were washed in Hank's solution, and resuspended at 5×10^6 cells/ml. They were then fixed by treating them for 10 minutes, at room
20 temperature, with 1% paraformaldehyde. Following fixation, they were washed, twice, in Hank's solution, and resuspended in Iscove's medium with 10% human serum added.

The cells were then distributed in 96V-bottom wells, at either 3×10^4 PBLs or 1×10^4 tumor cells, and pulsed with varying
25 concentrations of peptides. After two hours of incubation at 37°C , the cells were washed, twice, before CTLs (1500, 100 ul Iscove medium, 10% human serum, 20 U/ml recombinant human IL-2) were added, and TNF release from WEHI-164 cells measured. See, e.g., Traversari et al., Immunogenetics 35: 145 (1992),
30 incorporated by reference for particulars of the assay. The effector cells in the assay were from CTL 82/35.

The results are summarized in the following table. TNF was only produced in the presence of target cells, derived from patients who had tested positive for HLA-Cw*1601, based
35 upon the PCR assay, set forth supra, which had been pulsed with peptide.

The experiments, summarized in Table 1, used cells which had been fixed with glutaraldehyde, pulsed with the peptide, and then tested for recognition by cytolytic T cell line CTL
40 82/35. As the table shows, TNF was produced only in the presence of peptide pulsed target cells, which had tested

. 11

5 positive for HLA-Cw*1601 in the PCR assay discussed supra.

TABLE 1

10	Patient	HLA-Cw*1601 PCR	Peptide Presentation To CTL 82/35
15	MZ2	+	+
	LB17	+	+
	LB678	+	+
	LB708	+	+
	MI4024/1	+	+
20	LB73	-	-
	LY-2	-	-
	SK19	-	-
	SK37	-	-

25 Example 7

Approximately 8% of samples (7 of 99) were positive for this HLA type, and five of the positives were tested for CTL lysis; as described supra. All provoked lysis, as indicated in Table 1. In contrast, samples from four patients who were not positive for HLA-Cw*1601, did not provoke lysis by CTLs.

30 Example 8

In another experiment, MZ2 lymphoblastoid cells, infected with Epstein Barr Virus, were used in a ⁵¹Cr release assay. The infected cells, referred to as "MZ2-EBV", were ⁵¹Cr labelled, and then incubated for 30 minutes in the presence of MAGE-1 peptide, at concentrations ranging from 1 to 5000 nM. CTLs (either CTL 81/12 or CTL 82/35) were added at an effector/target ratio of 3:1. Chromium release was measured after four hours.

40 The results are shown in figures 2A and 2B, showing lysis by CTL 81/12 (figure 2A) and CTL 82/35 (figure 2B). Arrows indicate the level of lysis of MZ2-MEL 43(B⁻) and MZ2 lymphoblastoid cells (B⁻), incubated without peptides.

The experiments set forth supra suggest that a peptide

5 with a particular binding motif is required for binding to HLA-Cw*1601. Peptides of this formula, i.e.:

Xaa Ala (Xaa)₆ Leu

(SEQ ID NO: 10), are one feature of the invention. In SEQ ID NO: 10, Xaa refers to any amino acid, with the following preferences:

Ala or Ser at position 1

Tyr or Arg at position 3

Gly or Ala at position 4

Glu or Val at position 5

15 Pro or Phe at position 6

Arg or Leu at position 7

Lys or Ala at position 8

Isolated peptides of this formula are useful, e.g., in diagnosing cancer, as will be explained. It is known, as per the references cited herein, that patients do develop cytolytic T cells against their own tumors. For HLA-Cw*1601 positive patients, these cytolytic T cells recognize and react with any cell which presents complexes of HLA-Cw*1601 and a peptide of the formula in SEQ ID NO: 10, most preferably SEQ ID NO: 4 or SEQ ID NO: 5. The recognition may be monitored via TNF release by the CTLs, proliferation of the CTLs, and/or release of some agent contained by the target cells, e.g., radioactive chromium (⁵¹Cr). Thus, in one aspect of the invention, a sample of a subject's blood, containing PBLs, is contacted to HLA-Cw*1601 presenting cells. These cells are contacted, such as by pulsing, with a peptide in accordance with SEQ ID NO: 10. These peptides complex with the HLA-Cw*1601 molecules, and any CTLs in the PBL containing sample react therewith. Thus, one aspect of the invention is a diagnostic assay for the determination of tumor specific CTLs, it having been established that only tumor cells present MAGE derived TRAs. The one exception to this appears to be testicular cells, but it is a simple matter to simply exclude the possibility that CTLs in the subject's blood are reacting with testes cells. One may also transfect an HLA-Cw*1601 positive cell with a MAGE gene, e.g., MAGE-1, to produce the

5 desired complexes.

 In another aspect of the invention, the peptides disclosed herein may be used alone or complexed to carrier proteins, and then be used as immunogens. Such immunogens can be used alone, or preferably with a pharmaceutically acceptable adjuvant. The antibodies are useful, also in
10 diagnostic assays, to determine if and when the particular peptides are presented on cells. Again, such presentation is indicative of cancer.

 The isolated nucleic acid molecules of the invention are
15 also useful, as indicated, as probes for the determination of expression of HLA-Cw*1601. It hardly needs to be said that HLA typing is important in, e.g., tissue typing for transplantation, and other areas. Thus, it is useful to have available materials which can be used in this context. The
20 primers used in the PCR work can be used, alone or in combination, in amplification assays such as polymerase chain reaction. They can also be used, when labelled, e.g., radioactively or non-radioactively, as probes for determining whether or not HLA-Cw*1601 is expressed, in other diagnostic
25 assays. Thus, combinations of two or more of SEQ ID NOS: 6, 7, 8 and 9 may be used, in "one-pot" or kit forms, as diagnostic reagents. A kit form is expressly preferred, where separate portions of SEQ ID NOS: 6 and 7 and SEQ ID NOS: 8 and 9 are provided, in a packaging means, for use in an
30 amplification or other formats. The kits may also include polymerases, such as Taq polymerase, in specific embodiments.

 The foregoing experiments demonstrate that HLA-Cw*1601 presents a MAGE-1 derived peptide as a tumor rejection antigen, leading to lysis of the presenting cells. There are
35 ramifications of this finding, discussed infra. For example, CTL clone 81/12 is representative of CTLs specific for the complex in question. Administration of such CTLs to a subject is expected to be therapeutically useful when the patient presents HLA-Cw*1601 phenotype on abnormal cells. It is
40 within the skill of the artisan to develop the necessary CTLs in vitro. Specifically, a sample of cells, such as blood

5 cells, are contacted to a cell presenting the complex and capable of provoking a specific CTL to proliferate. The target cell can be a transfectant, such as a COS cell of the type described supra. These transfectants present the desired complex on their surface and, when combined with a CTL of
10 interest, stimulate its proliferation. It has been pointed out that the sequence for HLA-Cw*1601 is known to the art through GENBANK and EMBL, and the sequence for MAGE-1, together with a detailed protocol for its isolation, is provided by the PCT application and Van den Bruggen et al.,
15 both of which are incorporated by reference in their entirety, supra. COS cells, such as those used herein are widely available, as are other suitable host cells.

To detail the therapeutic methodology, referred to as adoptive transfer (Greenberg, J. Immunol. 136(5): 1917 (1986);
20 Riddel et al., Science 257: 238 (7-10-92); Lynch et al., Eur. J. Immunol. 21: 1403-1410 (1991); Kast et al., Cell 59: 603-614 (11-17-89)), cells presenting the desired complex are combined with CTLs leading to proliferation of the CTLs specific thereto. The proliferated CTLs are then administered
25 to a subject with a cellular abnormality which is characterized by abnormal cells presenting the particular complex. The CTLs then lyse the abnormal cells, thereby achieving the desired therapeutic goal.

The foregoing therapy assumes that the subject's abnormal
30 cells present the HLA-Cw*1601/MAGE-1 derived peptide complex. This can be determined very easily. For example CTLs are identified using the transfectants discussed supra, and once isolated, can be used with a sample of a subject's abnormal cells to determine lysis in vitro. If lysis is observed, then
35 the use of specific CTLs in such a therapy may alleviate the condition associated with the abnormal cells. A less involved methodology examines the abnormal cells for HLA phenotyping, using standard assays, and determines expression of MAGE-1 via amplification using, e.g., PCR.

40 Adoptive transfer is not the only form of therapy that is available in accordance with the invention. CTLs can also be

5 provoked in vivo, using a number of approaches. One approach, i.e., the use of non-proliferative cells expressing the complex, has been elaborated upon supra. The cells used in this approach may be those that normally express the complex, such as irradiated melanoma cells or cells transfected with
10 one or both of the genes necessary for presentation of the complex. Chen et al., Proc. Natl. Acad. Sci. USA 88: 110-114 (January, 1991) exemplify this approach, showing the use of transfected cells expressing HPVE7 peptides in a therapeutic regime. Various cell types may be used. Similarly, vectors
15 carrying one or both of the genes of interest may be used. Viral or bacterial vectors are especially preferred. In these systems, the gene of interest is carried by, e.g., a Vaccinia virus or the bacteria BCG, and the materials de facto "infect" host cells. The cells which result present the complex of
20 interest, and are recognized by autologous CTLs, which then proliferate. A similar effect can be achieved by combining MAGE-1 itself with an adjuvant to facilitate incorporation into HLA-Cw*1601 presenting cells. The enzyme is then processed to yield the peptide partner of the HLA molecule.

25 The foregoing discussion refers to "abnormal cells" and "cellular abnormalities". These terms are employed in their broadest interpretation, and refer to any situation where the cells in question exhibit at least one property which indicates that they differ from normal cells of their specific
30 type. Examples of abnormal properties include morphological and biochemical changes, e.g. Cellular abnormalities include tumors, such as melanoma, autoimmune disorders, and so forth.

Other aspects of the invention will be clear to the skilled artisan and need not be repeated here.

35 The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, it being recognized that various
40 modifications are possible within the scope of the invention.

5

SEQUENCE LISTING

(1) GENERAL INFORMATION:

10

(i) APPLICANTS: van der Bruggen, Pierre
Szikora, Jean-Pierre
Coulie, Pierre
Wildman, Claude
Boël, Pascale
Boon-Falleur, Thierry

15

(ii) TITLE OF INVENTION: METHOD FOR IDENTIFYING
INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY SOME OF
WHOSE ABNORMAL CELLS PRESENT COMPLEXES OF HLA-Cw*1601/MAGE-1
DERIVED PEPTIDES, AND METHODS FOR TREATING SAID INDIVIDUALS

20

(iii) NUMBER OF SEQUENCES: 10

25

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Felfe & Lynch
(B) STREET: 805 Third Avenue
(C) CITY: New York City
(D) STATE: New York
(E) COUNTRY: USA
(F) ZIP: 10022

30

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette, 5.25 inch, 360 kb
storage

35

(B) COMPUTER: IBM PS/2
(C) OPERATING SYSTEM: PC-DOS
(D) SOFTWARE: Wordperfect

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: 08/292,492
(B) FILING DATE: 18-AUG-1994
(C) CLASSIFICATION: 435

40

(vii) PRIOR APPLICATION DATA:

17

5 (A) APPLICATION NUMBER: 08/195,186
(B) FILING DATE: 14-FEB-1994

(vii) PRIOR APPLICATION DATA:

10 (A) APPLICATION NUMBER: 08/008,446
(B) FILING DATE: 22-JANUARY-1993

(viii) ATTORNEY/AGENT INFORMATION:

15 (A) NAME: Hanson, Norman D.
(B) REGISTRATION NUMBER: 30,946
(C) REFERENCE/DOCKET NUMBER: LUD 5361.1

(ix) TELECOMMUNICATION INFORMATION:

20 (A) TELEPHONE: (212) 688-9200
(B) TELEFAX: (212) 838-3884

18

5 (2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

10 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

ACTCCATGAG GTATTTTC

17

15

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 16 amino acid residues

(B) TYPE: amino acid

(D) TOPOLOGY: single

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

25

Glu His Ser Ala Tyr Gly Glu Pro Arg Lys Leu Leu Thr Gln Asp
Leu

5

10

15

30

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acid residues

35 (B) TYPE: amino acid

(D) TOPOLOGY: single

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

40 Glu His Ser Ala Tyr Gly Glu Pro Arg Lys Leu Leu

5

10

19

5

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9 amino acid residues

(B) TYPE: amino acid

10

(D) TOPOLOGY: single

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Ser Ala Tyr Gly Glu Pro Arg Lys Leu

5

15

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 9 amino acid residues

20

(B) TYPE: amino acid

(D) TOPOLOGY: single

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Ala Ala Arg Ala Val Phe Leu Ala Leu

5

25

(2) INFORMATION FOR SEQ ID NO: 6:

30

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

CAAGCGCCAG GCACAGA

17

40

20

5 (2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

10 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GCCTCATGGT CAGAGACGA

19

15

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 base pairs

20 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

25 GAGTGAGCCT GCGGAAC

17

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH: 18 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

35

CCTCCAGGTA GGCTCTCT

18

40 (2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

21

5 (A) LENGTH: 9 amino acid residues
(B) TYPE: amino acid
(D) TOPOLOGY: single
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

10 Xaa Ala (Xaa)₆ Leu

5 We claim:

1. Method for identifying a candidate for treatment with a therapeutic agent specific for complexes of HLA-C-clone 10 and the peptide of SEQ ID NO: 4, comprising:

10 (i) contacting an abnormal cell sample from a subject with a cytolytic T cell specific for said complexes, and

(ii) determining lysis of at least part of said abnormal cell sample as an indication of a candidate for said treatment.

15 2. Method for treating a subject with a cellular abnormality, comprising administering to said subject an amount of an agent which provokes a cytolytic T cell response to cells presenting complexes of HLA-C-clone 10 and the peptide of SEQ ID NO: 4 on their surfaces sufficient to provoke a response to abnormal cells presenting said complexes on their surfaces.

20 3. The method of claim 2, wherein said cellular abnormality is cancer.

4. The method of claim 3, wherein said cancer is melanoma.

25 5. The method of claim 2, wherein said agent comprises a vector which codes for the peptide of SEQ ID NO: 4.

6. The method of claim 5, wherein said agent further comprises a vector which codes for HLA-C-clone 10.

30 7. The method of claim 5, wherein said vector also codes for HLA-C-clone 10.

8. The method of claim 2, wherein said agent is a sample of non-proliferative cells which present said complexes on their surfaces.

35 9. Method for treating a cellular abnormality comprising administering to a subject with a cellular abnormality characterized by presentation of complexes of HLA-C-clone 10 and the peptide of SEQ ID NO: 4 on surfaces of abnormal cells an amount of cytolytic T cells specific for said complexes sufficient to lyse said abnormal cells.

40 10. The method of claim 9, wherein said cellular abnormality is cancer.

5 11. The method of claim 10, wherein said cancer is melanoma.

 12. The method of claim 9, wherein said cytolytic T cells are autologous.

10 13. Isolated cytolytic T cell which is specific for a complex of HLA-C-clone 10 and the peptide of SEQ ID NO: 4.

 14. Method for identifying an abnormal cell which presents a complex of HLA-C-clone 10 and the peptide of SEQ ID NO: 4 on its surface comprising contacting a sample of abnormal cells with a cytolytic T cell specific for said
15 complex and determining lysis of said abnormal cells as a determination of cells which present said complex.

 15. Isolated peptide selected from the group consisting of:

 SEQ ID NO: 2

20 SEQ ID NO: 3, and

 SEQ ID NO: 4.

 16. Isolated complex of HLA-C-clone 10 and the isolated peptide of SEQ ID NO: 4.

 17. Isolated nonapeptide of formula:

25 Xaa Ala (Xaa)₆ Leu

 (SEQ ID NO: 10)

 where Xaa is any amino acid.

30 18. Immunogenic composition comprising the isolated nonapeptide of claim 17 and a pharmaceutically acceptable adjuvant.

 19. The immunogenic composition of claim 18, wherein said isolated nonapeptide is complexed to a carrier protein.

 20. Isolated nucleic acid molecule useful in determining expression of HLA-Cw*1601, selected from the group consisting
35 of: SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9.

 21. Kit useful in determining expression of HLA-Cw*1601, comprising:

40 (a) a first reagent containing SEQ ID NO: 6 and SEQ ID NO: 7;

 (b) a second reagent containing SEQ ID NO: 8 and SEQ

5 ID NO: 9; and

(c) a packaging means for holding said first and second reagents.

22. The kit of claim 21, further comprising a separate portion of a polymerase.


10 23. Composition of matter useful in determining expression of HLA-Cw*1601 in a sample, comprising:

(a) a mixture of SEQ ID NO: 6 and SEQ ID NO: 7 or

(b) a mixture of SEQ ID NO: 8 and SEQ ID NO: 9.

15

FIGURE 1



2/2

CTL 81/12




Fig 2A

CTL 82/35




Fig 2B

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/01446

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 48/00; C12N 15/00; C12Q 1/00; C07K 7/00

US CL : 514/44; 424/93.21; 435/91, 7.24; 530/326, 327, 328

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/44; 424/93.21; 435/91, 7.24; 530/326, 327, 328

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
None

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DIALOG, APS

search terms: HLA-Cw*1601, MAGE-1 derived peptide, HLA-C clone 10

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Immunogenetics, Volume 35, issued 1992, Traversari et al., "Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes", pages 145-152, see entire reference.	1, 13-23
Y	Immunogenetics, Volume 37, issued 1993, Zemmour et al., "HLA class I nucleotide sequences, 1992", pages 239-250, see entire reference.	1, 13-23
Y	Science, Volume 257, issued 10 July 1992, Riddell et al., "Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones", pages 238-241, see entire reference.	1, 13-23



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

10 MAY 1995

Date of mailing of the international search report

24 MAY 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

SUZANNE ZISKA, PH.D.

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/01446

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Proceedings of the National Academy of Sciences USA, Volume 90, issued April 1993, Browning et al., "Tissue typing the <i>HLA-A</i> locus from genomic DNA by sequence-specific PCR: Comparison of <i>HLA</i> genotype and surface expression on colorectal tumor cell lines", pages 2842-2845, see entire reference.	1, 13-23

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No. .
PCT/US95/01446

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
1 and 13-23
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/01446

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

- I. Claims 1, 13 and 14, drawn to a method for identifying a candidate for treatment with a therapeutic agent comprising contacting an abnormal cell sample for a subject with a cytolytic T cell and determining lysis of at least part of said abnormal cell sample, classified in Class 435, subclass 7.24, for example;
- II. Claims 2-12, drawn to a method for treating a subject comprising administering an amount of an agent, classified in Class 424, subclass 93.21, for example;
- III. Claims 15 and 16, drawn to isolated peptides selected from the group consisting of SEQ ID NOs. 2-4 and the isolated complex of HLA-C-clone 10 and the isolated peptide of SEQ ID. No. 4, classified in Class 530, subclass 328, for example;
- IV. Claims 17-19, drawn to isolated nonapeptides, immunogenic compositions thereof and the isolated nonapeptide complexed to a carrier protein, classified in Class 530, subclasses 326-328, for example;
- V. Claims 20-23, drawn to a kit, classified in Class 435, subclass 91, for example.

The inventions listed as Groups I-V do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Group I is drawn to a method of identifying a candidate for treatment using a specific protocol which is not involved with or necessary to any of the other groups since the method of Group I uses starting materials and procedures not used by the other methods. Group II is a second method, drawn to a method of treating patients and does not require the method of Group I or the products of Groups III, IV or V. Groups III and IV are directed to the individual peptides alone or in combination with a carrier protein, represent unique sequences and therefore are independent. Note that although claim 17 appears to be a genus claim, that only 2 of the 9 amino acids are specified and therefore a search of the genus per se would result in a vast number of nonapeptides and a search of the genus would not necessarily result in the nonapeptides of the claimed invention. Group V is a method using PCR and is independent and distinct from any of the other methods, since the claimed method uses protocols and starting materials not used in the methods of the other inventions. Accordingly, the claims are not so linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept.